Analyzing the Role of Second-Line Ramucirumab in HCC

October 11, 2019
Ghassan K. Abou-Alfa, MD

Ghassan K. Abou-Alfa, MD, discusses the current role for ramucirumab for the treatment of patients with hepatocellular carcinoma in the second-line setting.

Ghassan K. Abou-Alfa, MD, from the Memorial Sloan Kettering Cancer Center, discusses the current role for ramucirumab (Cyramza) for the treatment of patients with hepatocellular carcinoma (HCC) in the second-line setting.

In May 2019, theFDA granted approval to ramucirumab monotherapy for the treatment of patients with HCC who have an alpha-fetoprotein (AFP) level of ≥400 ng/mLand have been previously treated with sorafenib (Nexavar), based on data from the phase III REACH-2 trial. For now, this agent is only applicable to patients with an elevated AFP above 400, says Abou-Alfa, but elevated AFP levels remain a complex piece of information.